Roche Venture Fund

The Roche Venture Fund is the corporate venture fund of Roche and invests in innovative life science companies. Over the past 20 years, the Roche Venture Fund has invested in over 60 companies globally and currently has a portfolio of around 30 companies located in 10 countries. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally and co-invests with leading venture funds, including other corporate venture funds, on a regular basis. https://www.roche.com/venturefund/

The Latest

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney diseaseAugust 5, 2026

Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has raised $46 million in a Series B funding round. Neil Wilkie, CEO of Mironid said: “ADPKD is the [...]

Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026

At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]

Q&A with David Henderson, Head of BiologyMarch 19, 2026

ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]